The development and future of oligonucleotide-based therapies for cervical cancer

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 2, 2007, Pages 126-131

  Gu, Wenyi ^a   Putral, Lisa N ^a   Irving, Aaron ^a   McMillan, Nigel A J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antisense oligonucleotide; HPV; Ribozyme; RNA interference

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; SMALL INTERFERING RNA;

APOPTOSIS; BIOTECHNOLOGY; CANCER COMBINATION CHEMOTHERAPY; GENE TARGETING; GENETIC DISORDER; HUMAN; IN VITRO STUDY; NONHUMAN; REVIEW; RNA INTERFERENCE; SENESCENCE; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; OLIGONUCLEOTIDES; RNA INTERFERENCE; RNA, SMALL INTERFERING; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 34247185985     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 118(12):3030-3044.
2. Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 24(Suppl 3):S11-S25.
3. Wright TC, Van Damme P, Schmitt HJ, Meheus A: Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine (2006) 24(Suppl 3):S122-S131.
4. Goodwin EC, DiMaio D: Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA (2000) 97(23):12513-12518.
5. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science (2002) 297(5578):63-64.
6. Chen Z, Kamath P, Zhang S, Weil MM, Shillitoe EJ: Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther (1995) 2(4):263-271.
7. Alvarez-Salas LM, Cullinan AE, Siwkowski A, Hampel A, DiPaolo JA: Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc Natl Acad Sci USA (1998) 95(3):1189-1194.
8. Venturini F, Braspenning J, Homann M, Gissmann L, Sczakiel G: Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: Anti-proliferative effects on HPV 16-transformed cells. Nucleic Acids Res (1999) 27(7):1585-1592.
9. Elbashir SM, Lendeckel W, Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 15(2):188-200. •• The first demonstration of siRNA in mammalian cells.
10. Jiang M, Milner J: Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene (2002) 21(39):6041-6048.
11. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F: siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene (2003) 22(38):5938-5945.
12. Hall AH, Alexander KA: RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol (2003) 77(10):6066-6069.
13. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, Yamato K: In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther (2003) 8(5):762-768. • This is the first paper describing siRNA treatment against HPV using in vivo models.
14. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, McMillan NA: RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol (2005) 68(5):1311-1319. • This is the first paper describing combination RNAi-chemotherapy treatments against HPV.
15. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G, McMillan NA: Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther (2006) 13(11):1023-1032. •• This is the first paper describing systemic in vivo RNAi treatments against HPV.
16. Niu XY, Peng ZL, Duan WQ, Wang H, Wang P: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer (2006) 16(2):743-751.
17. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B: Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 78(5):2601- 2605.
18. Tang S, Tao M, McCoy JP Jr, Zheng ZM: Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene (2006) 25(14):2094-2104.
19. Bai L, Wei L, Wang J, Li X, He P: Extended effects of human papillomavirus 16 E6-specific short hairpin RNA on cervical carcinoma cells. Int J Gynecol Cancer (2006) 16(2):718-729.
20. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, Williams C, Collingwood M: Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev (2005) (3):CD002225.
21. Jiang M, Rubbi CP, Milner J: Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides (2004) 14(4):239-248.
22. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, Lieberman J: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2006) 439(7072):89-94. •• The use of mucosal delivery of siRNA against virus infections is described.
23. Zhang Y, Cristofaro P, Silbermann R, Pusch O, Boden D, Konkin T, Hovanesian V, Monfils PR, Resnick M, Moss SF, Ramratnam B: Engineering mucosal RNA interference in vivo. Mol Ther (2006) 14(3):336-342.
24. Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, Ahmad I: Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol (2005) 26(4):1087-1091.
25. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 65(15):6910-6918.
26. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T et al: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest (2005) 115(4):978-985.
27. Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH: Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther (2002) 1(5):337-346.
28. Farhood H, Serbina N, Huang L: The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta (1995) 1235(2):289-295.
29. Akinc A, Thomas M, Klibanov AM, Langer R: Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med (2005) 7(5):657-663.
30. Sapra P, Tyagi P, Allen TM: Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv (2005) 2(4):369-381.
31. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 32(19):e149.
32. Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, Chang EH: Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther (2006) 17(1):117-124.
33. Pillai MR, Chacko P, Kesari LA, Jayaprakash PG, Jayaram HN, Antony AC: Expression of folate receptors and heterogeneous nuclear ribonucleoprotein E1 in women with human papillomavirus mediated transformation of cervical tissue to cancer. J Clin Pathol (2003) 56(8):569-574.
34. Koivusalo R, Krausz E, Helenius H, Hietanen S: Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: Opposite effect of siRNA in combination with different drugs. Mol Pharmacol (2005) 68(2):372-382.
35. NORTHERN ILLINOIS UNIVERSITY/US HEALTH (Hampel A, Dipaolo J, Siwkowski A, Galasinski SC): Human papilloma virus inhibition by a hairpin ribozyme. US-5683902 (1997).